Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Police protection for...

    Police protection for Drug Regulators, Inspectors, recommends CDSCO committee

    Farhat NasimWritten by Farhat Nasim Published On 2019-09-19T15:17:33+05:30  |  Updated On 19 Sep 2019 9:47 AM GMT
    Police protection for Drug Regulators, Inspectors, recommends CDSCO committee

    New Delhi: Taking cognizance of the grave concern of providing security and protection to Drug inspectors from threats, the Drugs Consultative Committee (DCC) of CDSCO has recently suggested that Drug Control Department of every State should be empowered with the police force of their respective state.


    The CDSCO committee directed to ensure that in every district at least one police officer is assigned for support in regulatory work related to Drugs and Cosmetics Act and other Act being enforced by State Drugs Control authorities.

    The suggestion came after going through a proposal to provide security measures to the drug regulators engaged in the enforcement activities of Drugs and Cosmetics Act, 1940 and related rules framed.


    DCC apprised that there are repeated cases in the news where intimidation, threat, looting and lynching with the drugs regulators have come to the knowledge. In one of the recent case, one officer of the FDA-Punjab was killed in the office due to her actions against the unaccounted and unauthorised sale of habit-forming drugs by a chemist.


    Medical Dialogues had earlier reported that in an appalling incident, a woman officer, posted as Zonal Licensing Authority with the Drug and Food Chemical Laboratory in the state was brutally murdered by a Chemist who took revenge on the officer for cancelling his Chemist License. Officer Neha Shorie, paid the price of her life for complying by her duty as she had cancelled the licence of a chemist shop in 2009. This led to the tragic incident wherein she was shot dead point-blank by the Chemist who later pumped a bullet into himself.


    Also Read: Shocking: Woman health officer shot dead for Cancelling Chemist Licence


    "All such incidences are making it unsafe to work individually by the regulators without adequate protection," the DCC was informed


    DCC deliberated the matter and suggested that Drug Control department of every state should be empowered with the police force of their respective state in line with Andhra Pradesh, Maharastra, Haryana etc. to protect the drug regulators from the threats.


    Accordingly, Drug Controllers may request their respective State Authorities for making such an arrangement or ensure that in every district at least one police officer is assigned for support in regulatory work related to Drugs and Cosmetics Act and other Act being enforced by State Drugs Control authorities.

    (DCC) CDSCO Chemist chemist license drug inspector drug officer shot drugs drugs consultative dept FDAPunjab inspector safety Neha Shorie Police police force punjab drug inspector safety measures state drug control dept 

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop production

      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop...

      Top priority on Delivery of Medicines through Speed Post: Minister

      Top priority on Delivery of Medicines through Speed Post: Minister

      Shipment of  antimalarial drug to US is likely to start next week: Indian Pharmaceutical Alliance

      Shipment of antimalarial drug to US is likely to start next week: Indian Pharmaceutical Alliance

      Lupin gets USFDA EIR for Nagpur Facility

      Lupin gets USFDA EIR for Nagpur Facility

      NPPA fixes prices of 29 formulations under DPCO, check out details

      NPPA fixes prices of 29 formulations under DPCO, check out details

      Coronavirus pandemic: Govt delegates more powers to NPPA to control, increase API production by manufacturers

      Coronavirus pandemic: Govt delegates more powers to NPPA to control, increase API production by...

      Aurobindo Pharma gets USFDA nod for Fluoxetine Tablets

      Aurobindo Pharma gets USFDA nod for Fluoxetine Tablets

      Aurobindo Pharma faces CA Suit in US for concealing facts

      Aurobindo Pharma faces CA Suit in US for concealing facts

      Jubilant Life Sciences Karnataka plant shut on coronavirus scare

      Jubilant Life Sciences Karnataka plant shut on coronavirus scare

      IPA releases Best Practices for Employee Safety in Pharmaceutical Manufacturing during COVID-19

      IPA releases Best Practices for Employee Safety in Pharmaceutical Manufacturing during COVID-19

      Coronavirus Impact: Indian Pharma Exports to miss 22 Billion target, says Pharmexcil

      Coronavirus Impact: Indian Pharma Exports to miss 22 Billion target, says Pharmexcil

      Bharat Biotech join hands with University of Wisconsin, FluGen for COVID-19 vaccine- CoroFlu

      Bharat Biotech join hands with University of Wisconsin, FluGen for COVID-19 vaccine- CoroFlu

      USFDA Requests Removal of All Ranitidine Products (Zantac) from the Market

      USFDA Requests Removal of All Ranitidine Products (Zantac) from the Market

      Popular Stories

      After Abbott, two more Stent makers seek withdrawal of New Gen Stents

      After Abbott, two more Stent makers seek withdrawal of New Gen Stents

      Sterling Biotech Bank Fraud: ED seize assets including business jet, ships, oil rings worth over Rs 9700 crore

      Sterling Biotech Bank Fraud: ED seize assets including business jet, ships, oil rings worth over Rs...

      3.36% of about 82,600 drugs samples found to be substandard

      3.36% of about 82,600 drugs samples found to be substandard

      Johnson n Johnson ties up with CSIR-IMTECH to Develop Innovative Tuberculosis Treatments

      Johnson n Johnson ties up with CSIR-IMTECH to Develop Innovative Tuberculosis Treatments

      Bring Cataract Lenses, Syringes, IV Fluid Sets, Urine Bags under Price Ceiling: Maha Govt tells Health Ministry

      Bring Cataract Lenses, Syringes, IV Fluid Sets, Urine Bags under Price Ceiling: Maha Govt tells...

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Johnson and Johnson must pay 4 million dollar in punitive damages in latest asbestos cancer trial

      Johnson and Johnson must pay 4 million dollar in punitive damages in latest asbestos cancer trial

      View All

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 27 May 2022 6:45 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
      verify here.

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
      X
      X